{"id":1006100,"date":"2026-09-28T06:03:25","date_gmt":"2026-09-28T10:03:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/"},"modified":"2026-09-28T06:03:25","modified_gmt":"2026-09-28T10:03:25","slug":"codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/","title":{"rendered":"Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA"},"content":{"rendered":"<div class=\"mw_release\">\n<p>REDWOOD CITY, Calif., Sept.  28, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DGIH54KmuWJaO7TEpdun0O0dlbtB03MphGY8LPACdghJhFln6IDaKLrjy_sBxfcBnrjCqAnUH94AWcI4Qamqrw==\" rel=\"nofollow\" target=\"_blank\"><u>Codexis<\/u><\/a>, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis<sup>\u00ae<\/sup> Manufacturing Platform.<\/p>\n<p>The agreement builds on advances presented at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Zilb5fM5pfJ2UrCyTWNF6kOspObEIN7PiE3o1ozPgpKPdBq5i8Fa_5QvYanbSnkdrBzHKN8gnyrgCTYe1Lo0BNVhrx99-3LGxz99-5w-T1_Sspx4yDzAQe0TzOqeJ8ogi5Lrb5eoQKTDckrzcBlNwg==\" rel=\"nofollow\" target=\"_blank\"><u>TIDES USA 2026<\/u><\/a>, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelect<sup>SM<\/sup>, a capability of ECO Synthesis.<\/p>\n<p>Under the agreement, Codexis will use its ECO Synthesis platform to produce stereo-defined oligonucleotide fragments through a fully enzymatic process. The fragments will be supplied to the innovator to assemble into the final duplex via ligation, an approach that is gaining momentum as a next-generation manufacturing paradigm for oligonucleotides due to its potential to enhance scalability, efficiency, and product quality.<\/p>\n<p>The collaboration will also compare enzymatically synthesized fragments with conventional solid-phase oligonucleotide synthesis (SPOS), evaluating purity, product quality, and ligation performance. The results will allow the innovator to assess the technology&#8217;s potential for future clinical development programs.<\/p>\n<p>Alison Moore, PhD., President and CEO at Codexis, said: \u201cThis agreement is an important next step in bringing our latest ECO Synthesis capabilities to a customer. Working with a pioneer in the siRNA field offers an exciting opportunity to demonstrate how ECO Synthesis can deliver stereochemical control, which may offer both superior product quality and therapeutic performance to an innovator\u2019s pipeline over assets produced using traditional solid phase chemistry methods.\u201d<\/p>\n<p>Codexis continues to advance the ECO Synthesis Manufacturing Platform as part of its strategy to industrialize scalable manufacturing solutions for complex oligonucleotide therapeutics.<\/p>\n<p>\n        <strong>About Codexis, Inc.<\/strong>\n      <\/p>\n<p>Codexis<sup>\u00ae<\/sup> is a leading provider of high-performance enzymatic solutions for efficient and scalable therapeutics manufacturing. The Company is currently developing its proprietary ECO Synthesis<sup>\u00ae<\/sup> Manufacturing Platform, an aqueous enzymatic process that may offer a scalable alternative to traditional solid phase organic synthesis of oligonucleotide manufacturing. Initially, Codexis is applying its technology to address the rapidly growing demand for RNAi therapeutics. Codexis\u2019 unique enzymes can drive improvements such as higher yields, increased purity, reduced energy usage and waste generation, stereoisomer control of siRNA, and improved overall capacity in manufacturing at substantially lower capital requirements, all of which may lead to greater efficiency and reduced costs. In addition, the Company supplies high-performance enzymes through its BioCatalysis business that are used in the manufacture of multiple commercially available small molecule therapeutics. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Wedw_jfCspr3jCGXrjFo2UM3p0E_pg4JIXYMbDNRMx4ll_4jZpUXdpNjW0MHCLH8139N5A62CS1DXKa801KmwtkfXT_BDrcBATYt7H4UjLCkGbKC6cMJlqMvTN5wmZ8l8NHzHrV4bCzlhtYO53-xZpUZUcpA0mehQfegfT-nfRxDqYBuD5Sis-ZwtXN9P8ZCIpVoKi4RghcFulXdC9i0aJ-2bZeHepWdPHGjlhavcfkE4aaXRY-nT3m1djAzAxn5OIzmdZmY-8t__hmgRBusmQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.codexis.com<\/a>.<\/p>\n<p>\n        <strong>For More Information<\/strong>\n      <\/p>\n<p>Investor Contact<br \/>Georgia Erbez<br \/>+1 (650) 421-8100<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-CTwD8lb0yQGfVHSRIcwJLnzUy348wHCHfWDEMfd5cdEqmcWUoRH3C7fZGcoI9t9lyjMkhTRrqUm4Ety7KYqezFVnjJGFUZQVCz7UQ5ulPH-qMdEeptiespVurR7vIn0MUymS9Mimkkj7SBh44HX57xYvCIQ4rmfcKQt3V5OX4_936eLq8TsHITGnrhWNbdDlFQXLW3f5Ge-_P8b_6Di9u-0otbGyQ9PCZ26ofoMIqE=\" rel=\"nofollow\" target=\"_blank\">ir@codexis.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDc3MyM3ODY2MDI3IzIwMTY1MzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjllYjVkOWItNzk0Mi00Mjk0LWFkMWQtNDRmZThmOTZkZmQwLTEwMjgxMDctMjAyNi0wOS0yOC1lbg==\/tiny\/Codexis-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) &#8212; Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis\u00ae Manufacturing Platform. The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelectSM, a capability of ECO Synthesis. Under the agreement, Codexis will use its ECO Synthesis platform to produce stereo-defined oligonucleotide fragments through a fully enzymatic process. The fragments will be supplied to the innovator to assemble into the final duplex via ligation, an approach that is gaining &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1006100","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) &#8212; Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis\u00ae Manufacturing Platform. The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelectSM, a capability of ECO Synthesis. Under the agreement, Codexis will use its ECO Synthesis platform to produce stereo-defined oligonucleotide fragments through a fully enzymatic process. The fragments will be supplied to the innovator to assemble into the final duplex via ligation, an approach that is gaining &hellip; Continue reading &quot;Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-28T10:03:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDc3MyM3ODY2MDI3IzIwMTY1MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA\",\"datePublished\":\"2026-09-28T10:03:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\\\/\"},\"wordCount\":438,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDc3MyM3ODY2MDI3IzIwMTY1MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\\\/\",\"name\":\"Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDc3MyM3ODY2MDI3IzIwMTY1MzQ=\",\"datePublished\":\"2026-09-28T10:03:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDc3MyM3ODY2MDI3IzIwMTY1MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDc3MyM3ODY2MDI3IzIwMTY1MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/","og_locale":"en_US","og_type":"article","og_title":"Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA - Market Newsdesk","og_description":"REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) &#8212; Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis\u00ae Manufacturing Platform. The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelectSM, a capability of ECO Synthesis. Under the agreement, Codexis will use its ECO Synthesis platform to produce stereo-defined oligonucleotide fragments through a fully enzymatic process. The fragments will be supplied to the innovator to assemble into the final duplex via ligation, an approach that is gaining &hellip; Continue reading \"Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-28T10:03:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDc3MyM3ODY2MDI3IzIwMTY1MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA","datePublished":"2026-09-28T10:03:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/"},"wordCount":438,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDc3MyM3ODY2MDI3IzIwMTY1MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/","name":"Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDc3MyM3ODY2MDI3IzIwMTY1MzQ=","datePublished":"2026-09-28T10:03:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDc3MyM3ODY2MDI3IzIwMTY1MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDc3MyM3ODY2MDI3IzIwMTY1MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1006100"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006100\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1006100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1006100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1006100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}